Thales Introduces S3NS in Partnership With Google Cloud and Unveils Its Offering in a First Step Towards the French Trusted Cloud Label
30.6.2022 15:20:00 EEST | Business Wire | Press release
Thales announced today the creation of S3NS, a French company designed to offer public and private organizations in France the power of Google Cloud, fully compliant with France's “Trusted Cloud” label, in partnership with Google Cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005160/en/
(Graphic: Thales)
The new company, majority owned and controlled by Thales, is under French law and follows the October 2021 partnership announcement between Thales and Google Cloud to jointly develop a locally-compliant Trusted Cloud offering. Thales and Google Cloud are committed to helping companies and public institutions to innovate and accelerate their digital transformation in ways that afford autonomy, compliant sovereignty, and the greatest possible benefits for their customers and users.
Meeting the French “Trusted Cloud”
S3NS will offer from the second half of 2024 its “trusted cloud” offering that will ultimately combine full performance, services and applications of Google Cloud technology while allowing protection against extraterritorial foreign laws and in compliance with the requirements of the “Trusted Cloud” label of France’s Information Systems Security Agency (ANSSI) in the frame of the French State strategy. S3NS will directly operate three data centers to ensure data and workload localisation in France. Both data center availability and engineering assistance will be available this year already and the recruitment of engineers who will operate the “Trusted Cloud” will begin.
A first milestone with an offering already available
S3NS' first offering is "Local control with S3NS", which will offer Google Cloud customers in France continued high public cloud performance, with added capabilities to localize clients’ data in France or in Europe, as needed or preferred. Customers will be able to restrict data access for administrative service and technical support solely to European Union locations. Cryptographic control of data access can be achieved with external encryption key management from S3NS. This first offering brings compliance with additional automation to simplify operations, along with additional auditability and transparency to increase customer confidence in cloud operations.
Committing partners already
To best support customers in this transition to the “Trusted Cloud”, S3NS is finalizing specific partnership agreements with various players in France's growing digital ecosystem. Partners will be able to support S3NS customers in their cloud and digital sovereignty strategy, as they migrate and operate their workloads and applications securely, with the help of S3NS’ and other managed services.
“The S3NS offering is the best of both worlds: the agility and wide range of services of a cloud hyperscaler combined with the security and data protection of a cybersecurity leader. This step marks the beginning of a technological and industrial adventure which will engage all the French economic players attached to a trusted solution. As a leader in critical information systems, Thales is once again demonstrating its ability to be a driving force in disruptive technologies.” Marc Darmon, Executive Vice President, Secure Communications and Information Systems at Thales.
“The creation of S3NS, progress on the definition of our Trusted Cloud offering and the availability of our 'Local controls with S3NS' is the result of many months of collaboration between Thales and the Google Cloud teams. This is a first step and a first milestone this year, before our future solution in compliance with the French 'Trusted Cloud' criteria, which we are working on in parallel. Our objective is to be the first to make such an offering available for certification and based on hyperscale cloud technology. 'Local Controls with S3NS' enables our customers to start their journey to the trusted cloud now.” Cyprien Falque, Managing director of S3NS.
“We are very proud to support our partner Thales and its subsidiary S3NS and its first offering in the French market. This collaboration between our teams reflects on the one hand an understanding of the expectations related to digital sovereignty, and on the other hand a real technological trajectory. We confirm the commitments made together in 2021 and will continue to support digital transformation with offers that combine security and sovereignty, without compromising on performance.” Thomas Kurian, CEO at Google Cloud.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021 the Group generated sales of €16.2 billion.
PLEASE VISIT
https://www.linkedin.com/company/s3nscloud/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005160/en/
Contact information
Press
Thales, Media Relations
Security
Marion Bonnet
marion.bonnet@thalesgroup.com
+33(0)660384892
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom